Proteome Sciences, a global leader in applied proteomics, uses high sensitivity proprietary technologies to detect biomarkers (differentially expressed proteins in diseases). The biomarkers discovered in body fluids or tissues are validated, developed and commercialised as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP® toolkit, Proteome Sciences provides high sensitivity/high throughput proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology and diagnostic companies, to discover and exploit protein biomarkers. Sensitizer® chemical mass tags have been developed separately as a series of stand-alone reagents.

Since its inception in 1994, Proteome Sciences has discovered a large number of novel protein biomarkers in key human diseases and has established a broad portfolio of products/licensing from Intellectual Property (IP) related to differential protein expression.

Proteome Sciences has state-of-the-art, research facilities in London, UK
and Frankfurt, Germany. These are complemented through a range of
collaborations with leading academic research establishments worldwide.

Proteome Sciences has made investments in two associated companies: Intronn Inc., based in Gaithersburg, USA, involved in RNA therapy with SMaRT™ technology and Veri-Q Inc. in Raleigh-Durham, USA, for developing quality control (QC) in synthetic oligonucleotide production and reagents.